Welcome to our dedicated page for Aptorum Group SEC filings (Ticker: APM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if Aptorum’s latest clinical trial milestone affects valuation or whether new shares are hitting the market? This dedicated Aptorum Group SEC filings hub brings every disclosure into one place and turns dense biotech language into clear insights.
Use Stock Titan’s AI-powered summaries to move straight to the numbers that matter: R&D spending, cash runway, and pipeline updates buried deep in the Aptorum Group annual report 10-K simplified or the Aptorum Group quarterly earnings report 10-Q filing. Real-time alerts flag Aptorum Group Form 4 insider transactions real-time so you can track executive stock moves before the market reacts. Our platform also connects each Aptorum Group 8-K material events explained with context on clinical partnerships, capital raises, and licensing deals.
Need hard data fast? Skip scrolling through EDGAR and head straight to:
- 10-K & 10-Q for detailed pipeline timelines, trial costs, and dilution analysis—perfect for “Aptorum Group earnings report filing analysis”.
- Form 4 for “Aptorum Group executive stock transactions Form 4” and “Aptorum Group insider trading Form 4 transactions”.
- DEF 14A proxy for “Aptorum Group proxy statement executive compensation”.
- 8-K updates on strategic collaborations, drug approvals, or adverse events.
Whether you’re understanding Aptorum Group SEC documents with AI for the first time or comparing quarter-over-quarter progress, Stock Titan keeps you ahead with expert analysis, complete coverage, and filing-time alerts that land seconds after EDGAR posts.
Aptorum Group (APM) completed a registered direct financing, selling 1,000,000 Class A ordinary shares and issuing, in a concurrent private placement, restricted warrants to purchase up to 2,000,000 shares, for aggregate gross proceeds of about $2 million. The warrants are exercisable immediately at $2.00 per share and expire 24 months from the effective date of a resale registration statement for the warrant shares. The transaction closed on October 14, 2025.
H.C. Wainwright & Co. acted as exclusive placement agent. Fees include 7% of gross proceeds, a 1% management fee, specified expenses, and clearing fees. Aptorum expects net proceeds of approximately $1.725 million, to be used for working capital and to help fund expenses tied to the previously announced DiamiR Biosciences merger, which remains subject to closing conditions. The company agreed to a 30‑day issuance lock-up, and officers and directors agreed to a 30‑day sale lock-up following closing.
Aptorum Group (APM) furnished DiamiR Biosciences’ quarterly financials and related MD&A for the quarter ended August 31, 2025. This update is tied to the previously announced plan for Aptorum to merge its newly formed Delaware subsidiary with DiamiR, leaving DiamiR as a wholly owned subsidiary. The Merger remains subject to Aptorum shareholder approval and the satisfaction or waiver of other closing conditions set out in the Merger Agreement.
The furnished materials are incorporated by reference into Aptorum’s existing registration statements on Form S-8 (No. 333-232591) and Form F-3 (No. 333-268873), making the DiamiR disclosures part of those offerings’ prospectuses. The filing also includes the Merger Agreement reference and Inline XBRL exhibits.
Aptorum Group Ltd (APM) is proposing a business combination with DiamiR that would domesticate the Cayman Islands parent into a Delaware corporation and reorganize its share capital while issuing Aptorum Delaware shares to DiamiR shareholders under a defined Conversion Ratio. Key transaction mechanics include a Share Consolidation (reverse split) to be set by the board before domestication, issuance scenarios that would produce up to
The filing discloses commercial and operational ties: an Intellectual Property License Agreement with an upfront payment of